geometric mean titer – Page 6 – Communicable Diseases Research

IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients

SARS-COV-2 뉴 클레오 캡시드 단백질에 대한 IgG 항체 역가 COVID-19 환자의 중증도와 상관 관계가있다.

Research

Published on 2021-12-182022-09-01
Journal: BMC Microbiology [Category] SARS, 진단, 치료기술, 치료법,

A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults

Article

Published on 2021-12-142022-10-04
Journal: Nature Communications [Category] SARS, 유전자 메커니즘, 임상, 치료법,

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents

청소년의 mRNA-1273 SARS-CoV-2 백신 평가

Clinical Trial

Published on 2021-12-092022-09-12
Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상, 진단,

[키워드] 95% CI 95% confidence interval absolute difference acute respiratory syndrome Administered Adolescent Adults Adverse reaction age assigned Asymptomatic coronavirus coronavirus disease criterion development Efficacy fatigue geometric mean titer headache healthy immune response incidence Infection injection Injection-site pain Moderna mRNA-1273 mRNA-1273 vaccine occurred participant Participants phase 3 trial Placebo placebo-controlled trial pseudovirus neutralizing antibody Randomly receive reported safety profile SARS-CoV-2 Secondary objective Serious Adverse Event Serologic response the placebo group the vaccine
[DOI] 10.1056/NEJMoa2109522 PMC 바로가기 [Article Type] Clinical Trial

The Impact of Age Difference on the Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis

연령 차이가 COVID-19 백신의 효능 및 안전성에 미치는 영향: 체계적인 검토 및 메타 분석

Meta-Analysis

Published on 2021-12-062022-09-12
Journal: Frontiers in Immunology [Category] SARS, 진단,

Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in Healthy Adults

건강한 성인을 대상으로 한 비활성화된 중증 급성 호흡기 증후군 코로나바이러스 2 백신에 대한 무작위, 이중 맹검, 위약 대조 2상 시험

Clinical Trial

Published on 2021-12-062022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse reaction Adverse reactions anti-N antibodies anti-N antibody anti-S antibody clinical Controlled trial coronavirus coronavirus 2 dose double-blinded enrolled evaluated geometric mean geometric mean titer geometric mean titers GMT GMTs groups HD group healthy High dose immunization immunogenicity inactivated Inactivated SARS-CoV-2 vaccine medium dose neutralizing antibody Phase 2 phase 2 trial Randomized respiratory Safety safety analysis SARS-CoV-2 SARS-CoV-2 vaccine Serious Adverse Event Serious Adverse Events seroconversion rate seroconversion rates study period subject the vaccine Trial Vaccine
[DOI] 10.1093/cid/ciaa1703 PMC 바로가기 [Article Type] Clinical Trial

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon

상동 BNT162b2 백신과 비교하여 BBIBP-CorV 백신을 접종한 개인에서 BNT162b2 부스터의 면역원성 및 반응성: 레바논의 파일럿 전향 코호트 연구 결과

Article

Published on 2021-11-052022-09-11
Journal: Vaccine [Category] SARS, 변종,

Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies

RBD IgG와 중화항체를 모두 사용한 BNT162b2 SARS-CoV-2 mRNA 백신에 대한 신장 이식 수혜자의 체액 반응

Observational Study

Published on 2021-11-012022-09-11
Journal: Transplantation [Category] MERS, SARS, 임상, 진단, 치료기술,

[키워드] 95% CI 95% confidence interval Antibody Response Blood level BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine BNT162b2 vaccine Control control group daily dose develop Dilution domain dose Efficacy geometric mean geometric mean titer geometric mean titers group hemoglobin humoral Humoral response IgG Immunoglobulin Immunoglobulin G increase in independent predictor independent predictors injection injection site mRNA multivariable analysis mycophenolic acid Neutralizing antibodies neutralizing antibody Odds ratio Patient positive positive response predictor pseudo-virus RBD RBD IgG Receptor-binding domain recipient reduced renal Responder responders response response rate SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines significantly significantly higher significantly lower the antibody response Transplant vaccine dose
[DOI] 10.1097/TP.0000000000003889 PMC 바로가기 [Article Type] Observational Study

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

예방 접종을 받은 의료 종사자의 Covid-19 돌발 감염

Article

Published on 2021-10-142022-09-11
Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 변종,

[키워드] 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ag-RDT Alpha Analysis Antibody titer Antibody titers Antigen assays Asymptomatic B.1.1.7 BNT162b2 Breakthrough infection breakthrough infections Case-control Control coronavirus correlated correlation Ct value cycle threshold diagnostic diagnostic testing Efficacy estimating equation FIVE genomic sequencing geometric mean geometric mean titer geometric mean titers Health care Health care worker health care workers high viral load Infection Messenger RNA Mild mild symptoms MOST N gene Neutralizing antibody titer neutralizing antibody titers occur Occurrence Patient patients positive result predict reported RT-PCR SARS-CoV-2 SARS-CoV-2 detection Secondary infection secondary infections serologic assays severe acute respiratory syndrome Coronavirus Symptom symptomatic tested The B.1.1.7 titers two groups uninfected control Vaccine variant Viral load were assessed worker
[DOI] 10.1056/NEJMoa2109072 PMC 바로가기 [Article Type] Article

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

청소년 및 노인의 SARS-COV-2 재조합 스파이크 단백질 백신 (NVX-COV2373)의 상이한 용량 요법 : 2 상 무작위 위약 대조 시험

Clinical Trial

Published on 2021-10-012022-08-13
Journal: PLoS Medicine [Category] Biochemistry, MERS, SARS, 임상, 진단,

[키워드] 95% CI 95% confidence interval accumulate addition Administered Adults adverse events age Anti-spike Antibody Response assessments assigned composed conducted convalescent sera coronavirus Day dose dose regimen Efficacy Endpoint Enrollment exceeded Follow-up Formica Frequency full-length SARS-CoV-2 geometric mean geometric mean titer geometric mean titers GMTs group groups identify IgG immune persistence immune response immune responses immunogenic immunogenicity Immunoglobulin Immunoglobulin G include inhibitory concentration intensity intramuscular dose lack limitation Matrix-M1 adjuvant median Mild mild to moderate moderate neutralizing antibody Neutralizing antibody response neutralizing antibody responses NVX-CoV2373 occurred less Older Older adults participant Participants Phase 1 Phase 2 Placebo placebo-controlled placebo-controlled trial primary endpoints Protein Randomized randomized placebo-controlled trial Randomly reactogenicity receive Recombinant spike protein regimen researcher respiratory Respiratory Coronavirus robust safety follow-up SARS-CoV-2 second dose second vaccination secondary endpoint seroconversion rate seroconversion rates severity short duration spike glycoprotein spike glycoproteins Spike protein Support The United States These data Tolerability Treatment Trial Trial registration trimeric United States USA vaccination Vaccine vaccine group wild-type virus
[DOI] 10.1371/journal.pmed.1003769 PMC 바로가기 [Article Type] Clinical Trial

Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients

Research Article

Published on 2021-09-222022-10-30
Journal: Microbiology Spectrum [Category] COVID-19, MERS, SARS,

[키워드] 95% CI 95% confidence interval acute phase acute respiratory syndrome administration age anti-SARS-CoV-2 antibody antibodies antibody Characteristics China collected conducted convalescent COVID-19 patient Convalescent patients coronavirus coronavirus disease COVID-19 COVID-19 convalescent patient COVID-19 patient Dilution discharge discharged disease severity enrolled Evidence Factor Follow-up follow-up period follow-up time geometric mean titer GMT hospital IgG IgM IgM/IgG immune response inhibitory interquartile range Jiangsu Kinetics male median Month natural infection Neutralizing activity neutralizing antibody Onset participant Patient patients persistence plasma sample produced SARS-CoV-2 serological seropositive serum sample severity significantly higher significantly lower Specific Standard deviation symptom onset tested Vaccine virus dynamics with COVID-19
[DOI] 10.1128/Spectrum.00590-21 PMC 바로가기 [Article Type] Research Article